UNSPSC 51161552: Pirolate

This classification denotes an anti-asthmatic agent with the molecular formula C16H15N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2LF7L6QD58, chemically known as pyrimido(4,5-b)quinoline-2-carboxylic acid, 1,4-dihydro-7,8-dimethoxy-4-oxo-, ethyl ester but generally known as pirolate, which bears US NIH Compound Identifier 5361200. European Medicines Agency schedules Pirolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09932MIG.

UNSPSC 51161552 Pirolate is a Commodity code under which state and local governments procure generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers to public facilities including healthcare, corrections, and other institutional settings. The work involves manufacturers supplying comprehensive product catalogs with specific National Drug Codes, SKUs, UPCs, and dosage specifications; compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act; and flexible pricing models negotiated through cooperative purchasing vehicles. Issuing bodies are primarily state agencies and multistate consortia administering pooled procurement on behalf of participating state and local government facilities, schools, and transit authorities seeking standardized pharmaceutical sourcing agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. MMCAP's scope includes participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of the three; awarded vendors will be provided to wholesalers by May 15, 2026, with resulting agreements effective July 1, 2026. Evaluation is weighted heavily toward price competitiveness (75 percent), with smaller weights on fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new responders with optional MMCAP extensions, or alignment with incumbent agreement expiration through June 30, 2028.